Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

President Trump has threatened to slap a 200% tariff on foreign-made pharmaceuticals. That would roil the $200 billion-plus ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

AI is reshaping life sciences. Learn how compliant, explainable, and genuinely useful systems move from pilot to scale and ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

The country’s biggest pharmaceuticals group pointed to “specific non-allied countries” and urged the White House to ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...